Part 3 Flashcards
Agonist
Binds to the active site of the receptor and causes a conformational change of the receptor resulting in activation of the receptor which results in cellular response
Antagonist
Binds to active site of the receptor but does not cause a conformational change which is necessary for activation
*prevents agonists from binding and activating the receptor
Allosteric modulators
Binds to the site on the receptor other than the agonist binding site and thus inhibit or potentiate the receptor response to agonist
Competitive antagonism
Agonist occupancy at a given agonist concentration is reduced because the agonist and the antagonist are both binding to the active site. Because the receptor active site can only be bound to one molecule at a time
Why is competitive antagonism surmountable
Because the agonist and the antagonist both compete for the same binding site, increasing the concentration of the agonist will restore agonist occupancy and
tissue response
What happens to the graph in competitive antagonism
*the slope remains the same
*shape also remains the same
*the curve shifts to the right
*C50 increases
*Emax remains the same
How and why does the Emax and C50 remain the same
*the C50 shifts to the right and increases because you need more more of the drug to reach max effect
*Emax remains the same cause you will still reach the same max effect it will just take longer
Examples of agonists and antagonists in competitive antagonism
a and b adrenoceptors
Agonists- noradrenaline,isoprenaline
Antagonists-propranolol
Opiod receptors
Agonist-
Morphine
Heroin
Etorphine
Antagonists- naloxone, diprenorphine
Analgesic
Relieves pain
Irreversible antagonism
When an antagonist binds to the receptor and forms a covalent bond with the receptor or binds so tightly to the receptor that the receptor is no longer available to bind to agonist
Effects on C50 and Emax irreversible antagonism
C50 remains same
Emax decreases
Phenoxybenzamine
An irreversible a adrenoceptor used to control hypertension caused by catecholaminws released by pheochromocytoma, a tumour in adrenal medulla
Allosteric modulator
Non competitive inhibitor that binds to site other than active site and changes affinity of receptor for agonist to inhibit or potentiate it
Allosteric activator
Binds to Allosteric site of receptor and potentiate the effect of agonists
Benzodiazepines
Allosteric activatorsthat potentiate the effects of aminobutyric acid (GABA) at GABAa receptor